A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | Aplastic Anemia & MDS International Foundation
  1. Treatments
  2. Clinical Trials
  3. A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

Clinical Trial: NCT01953692

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
https://clinicaltrials.gov/ct2/show/NCT01953692
Purpose: 

The purpose of this trial is to evaluate the safety, tolerability, and efficacy of pembrolizumab (MK-3475, KEYTRUDA®) in hematologic malignancies. The primary study hypotheses are that treatment with pembrolizumab will result in a clinically meaningful improvement in Objective Response Rate (ORR) or Complete Remission Rate (CRR)

Status: 
Recruiting
Study Date: 
Fri, 11/01/2013 to Sun, 01/01/2017
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Lenalidomide
Intervention: 
Biological: Pembrolizumab IV infusion Other Names: MK-3475 KEYTRUDA® Drug: Lenalidomide oral capsules Other Name: REVLIMID®